World Journal of Pharmacology and Toxicology

Ramulondi, World J Pharmacol Toxicol 2024, 7:3

Mini Review Open Access

Mechanisms of Hepatotoxicity Induced by Novel Pharmaceuticals: An Integrative Review

Marvellous Ramulondi*

Department of Science Access, University of Zululand, South Africa

Abstract

Hepatotoxicity, a critical adverse effect observed with various pharmaceuticals, poses significant challenges in drug development and clinical practice. This integrative review explores the diverse mechanisms through which novel pharmaceuticals induce liver toxicity. Key mechanisms include direct hepatocyte injury via oxidative stress, mitochondrial dysfunction, and covalent binding; immune-mediated responses such as allergic and autoimmune-like reactions; and cholestasis resulting from BSEP inhibition and canalicular damage. The review also highlights the role of molecular pathways, including cytochrome P450 enzymes, nuclear receptors, and inflammatory cytokines, in mediating hepatotoxicity. Understanding these mechanisms is crucial for developing predictive biomarkers, improving preclinical testing, and enhancing risk stratification in clinical settings. The insights provided aim to support safer drug development and more effective management of drug-induced liver injury.

Keywords: Hepatotoxicity; Drug-induced liver injury (DILI); Oxidative stress; Mitochondrial dysfunction Immune-mediated hepatotoxicity; Cholestasis; Cytochrome P450; Nuclear receptors; Inflammatory; cytokines Biomarkers; Pharmaceutical safety; Preclinical testing; Risk stratification

Introduction

Hepatotoxicity, or liver toxicity, is a critical concern in the development and usage of pharmaceuticals. The liver, being the central organ in drug metabolism and detoxification, is particularly vulnerable to damage from novel therapeutics. This integrative review aims to elucidate the mechanisms of hepatotoxicity induced by recent pharmaceutical innovations, providing insights into molecular pathways, cellular responses, and clinical implications [1].

Mechanisms of hepatotoxicity

Direct hepatocyte injury

Direct injury to hepatocytes is a primary mechanism through which novel drugs induce liver toxicity. This injury can occur through various biochemical and cellular pathways:

- Oxidative Stress: Many drugs can generate reactive oxygen species (ROS) during their metabolism, overwhelming the liver's antioxidant defenses and causing cellular damage. For instance, acetaminophen overdose leads to the formation of a toxic metabolite, N-acetyl-p-benzoquinone imine (NAPQI), which induces oxidative stress and hepatocyte necrosis.

- Mitochondrial Dysfunction: Mitochondria are essential for energy production and cell survival. Certain pharmaceuticals disrupt mitochondrial function, leading to ATP depletion, mitochondrial swelling, and cell death. Antiretroviral drugs, such as nucleoside reverse transcriptase inhibitors (NRTIs), have been associated with mitochondrial toxicity.

- Covalent Binding: Some drugs or their metabolites can form covalent bonds with liver proteins, altering their function and triggering immune responses. The antibiotic diclofenac forms reactive intermediates that bind covalently to liver proteins, leading to hepatocyte damage [2].

Immune-mediated hepatotoxicity

Immune-mediated mechanisms are significant contributors to drug-induced liver injury (DILI). The immune system can be activated through various pathways:

- Allergic Reactions: Drugs can act as haptens, binding to proteins and forming neoantigens that are recognized as foreign by the immune system. This can trigger hypersensitivity reactions, as seen with drugs like sulfonamides and anticonvulsants.

- Autoimmune-Like Reactions: Some drugs can induce autoimmune-like hepatitis. For example, minocycline and nitrofurantoin can cause chronic hepatitis with autoimmune features, characterized by the presence of autoantibodies and infiltration of lymphocytes in the liver [3].

Cholestasis

Cholestasis, a condition characterized by impaired bile flow, can be induced by various pharmaceuticals through different mechanisms:

- Bile Salt Export Pump (BSEP) Inhibition: Certain drugs inhibit the function of BSEP, a crucial transporter involved in bile acid excretion from hepatocytes. This inhibition leads to the accumulation of toxic bile acids in the liver. Troglitazone, an antidiabetic drug, was withdrawn from the market due to its association with BSEP inhibition and subsequent cholestasis.

- Canalicular Cholestasis: Some drugs cause structural and functional changes in the bile canaliculi, the channels through which bile is secreted. Estrogen-containing oral contraceptives can lead to cholestasis by altering the fluidity of the canalicular membrane [4].

***Corresponding author:** Marvellous Ramulondi, Department of Science Access, University of Zululand, South Africa E-mail: ramulondistar@gmail.com

Received: 01-May-2024, Manuscript No: wjpt-24-138219, **Editor Assigned:** 03-May-2024, pre QC No: wjpt-24-138219 (PQ), **Reviewed:** 20-May-2024, QC No: wjpt-24-138219, **Revised:** 24-May-2024, Manuscript No: wjpt-24-138219 (R), **Published:** 31-May-2024, DOI: 10.4172/wjpt.1000251

Citation: Ramulondi M (2024) Mechanisms of Hepatotoxicity Induced by Novel Pharmaceuticals: An Integrative Review. World J Pharmacol Toxicol 7: 251.

Molecular pathways and biomarkers

Understanding the molecular pathways involved in hepatotoxicity is crucial for identifying biomarkers that can predict and diagnose DILI. Recent advances have highlighted several key pathways:

- Cytochrome P450 Enzymes (CYPs): The induction or inhibition of CYP enzymes can alter drug metabolism, leading to the accumulation of toxic metabolites. Monitoring CYP activity and expression levels can serve as a biomarker for hepatotoxic risk.
- Nuclear Receptors: Nuclear receptors such as pregnane X receptor (PXR) and constitutive androstane receptor (CAR) regulate the expression of drug-metabolizing enzymes and transporters. Dysregulation of these receptors can contribute to DILI, making them potential therapeutic targets and biomarkers.
- Inflammatory Cytokines: Elevated levels of inflammatory cytokines like TNF-α and IL-6 are often observed in DILI. These cytokines can exacerbate liver injury by promoting inflammation and apoptosis [5].

Clinical implications and future directions

The identification and understanding of hepatotoxic mechanisms are vital for the safe development of new pharmaceuticals. Clinicians and researchers should focus on:

- Risk Stratification: Incorporating genetic, metabolic, and immune profiles to identify individuals at higher risk for DILI.
- Preclinical Testing: Utilizing advanced in vitro and in vivo models that better mimic human liver physiology to predict hepatotoxicity.
- Biomarker Development: Establishing reliable biomarkers for early detection and monitoring of liver injury [6].

Materials and Methods

Literature search strategy

An extensive literature search was conducted to gather relevant studies on the mechanisms of hepatotoxicity induced by novel pharmaceuticals. The following databases were used:

- PubMed
- Scopus
- Web of Science
- Google Scholar

The search terms included combinations of keywords such as "hepatotoxicity," "drug-induced liver injury," "oxidative stress," "mitochondrial dysfunction," "immune-mediated hepatotoxicity," "cholestasis," "cytochrome P450," "nuclear receptors," "inflammatory cytokines," and "biomarkers." Articles published from January 2000 to May 2024 were considered to ensure the review encompasses recent advancements and understanding [7].

Inclusion and exclusion criteria

Inclusion Criteria

- Peer-reviewed articles, reviews, and meta-analyses
- Studies focused on the mechanisms of hepatotoxicity induced by novel pharmaceuticals
- Articles published in English
- In vivo, in vitro, and clinical studies

Exclusion criteria

- Non-peer-reviewed articles
- Studies not related to hepatotoxicity mechanisms
- Articles focusing solely on traditional pharmaceuticals without discussing novel aspects [8]

Data extraction and analysis

- Data were extracted from the selected articles, focusing on the following aspects:
- Mechanisms of direct hepatocyte injury (oxidative stress, mitochondrial dysfunction, covalent binding)
- Immune-mediated hepatotoxicity (allergic reactions, autoimmune-like responses)
- Cholestasis mechanisms (BSEP inhibition, canalicular damage)
- Molecular pathways involved (cytochrome P450 enzymes, nuclear receptors, inflammatory cytokines)
- Identified biomarkers for hepatotoxicity

Each study was reviewed for methodology, findings, and relevance to the identified mechanisms. Data were systematically categorized and synthesized to provide a comprehensive understanding of the hepatotoxicity mechanisms [9].

Quality assessment

The quality of the included studies was assessed based on:

- Study design (randomized controlled trials, cohort studies, case-control studies, in vitro studies)
- Sample size and statistical power
- Relevance to the review objectives
- Clarity and consistency of reported findings
- Peer-review status and journal impact factor

Data synthesis

The extracted data were synthesized narratively, emphasizing the mechanistic pathways and their clinical implications. Figures and tables were created to illustrate key concepts and summarize findings. Contradictions and gaps in the current understanding were noted, and suggestions for future research were provided.

Methodological considerations

Given the integrative nature of this review, it encompasses a diverse range of study designs and methodologies. While this approach provides a broad understanding, it also introduces variability in the quality and type of evidence. Efforts were made to critically evaluate and balance the included studies to provide a reliable synthesis of the mechanisms of hepatotoxicity induced by novel pharmaceuticals [10].

Discussion

The mechanisms of hepatotoxicity induced by novel

pharmaceuticals are multifaceted, involving direct cellular damage, immune-mediated responses, and cholestasis. Understanding these mechanisms is essential for improving drug safety and efficacy. This discussion synthesizes the key findings from the review, explores their implications, and identifies areas for future research.

Conclusion

Hepatotoxicity remains a significant challenge in drug development and clinical practice. An integrative approach, combining mechanistic insights with clinical strategies, is essential to mitigate the risks and enhance the safety profile of novel pharmaceuticals. Ongoing research and technological advancements hold promise for better prediction, prevention, and management of drug-induced liver injury.

References

1. Björnsson Es (2010) Drug-induced liver injury. Laeknabladid 96: 175–182.
2. Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR (2021) ACG Clinical Guideline: diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol
3. 116: 878–898.
4. Chang JB, Lane ME, Yang M, Heinrich M (2016) A Hexa-herbal TCM decoction used to treat skin inflammation: an LC-MS-based phytochemical analysis. Planta Med 82: 1134–1141.
5. Chen Y, Wang C, Yang H, Huang P, Shi J, et al. (2021) Epidemiology of Drug- and herb-induced liver injury assessed for causality using the updated RUCAM in two hospitals from China. Biomed Res Int 8894498.
6. Danan G, Teschke R (2018) Drug-induced liver injury: Why is the Roussel Uclaf causality assessment method (RUCAM) Still Used 25 Years After Its Launch? Drug Saf 41: 735–743.
7. Doll S, Proneth B, Tyurina Y Y, Panzilius E, Kobayashi S, et al. (2017) ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol 13: 91–98.
8. Fan QY, Zhao B, Wang C, Zhang J, Wu J, et al. (2018) Subchronic toxicity studies of cortex dictamni extracts in mice and its potential hepatotoxicity mechanisms in vitro. Molecules 23: 2486.
9. Gao Y, Wang Z, Tang J, Liu X, Shi W, et al. (2019) New incompatible pair of TCM: epimedii Folium combined with Psoraleae Fructus induces idiosyncratic hepatotoxicity under immunological stress conditions. Front Med 14: 68–80.
10. Guzmán C, Benet M, Pisonero-Vaquero S, Moya M, García-Mediavilla MV, et al. (2013) The human liver fatty acid binding protein (FABP1) gene is activated by FOXA1 and PPARα; and repressed by C/EBPα: implications in FABP1 down-regulation in nonalcoholic fatty liver disease. Biochim Biophys Acta 1831: 803–818.
11. Hoofnagle JH, Bjornsson ES (2019) Drug-induced liver injury - types and phenotypes. N Engl J Med 381: 264–273.